eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy


Autoři: Chung-I. Huang aff001;  Chih-Chun Wang aff002;  Tzong-Shyuan Tai aff003;  Tzer-Zen Hwang aff002;  Chuan-Chien Yang aff002;  Chin-Mu Hsu aff004;  Yu-Chieh Su aff004
Působiště autorů: Department of Radiation Oncology, E-Da Cancer Hospital, Kaohsiung, Taiwan aff001;  Department of Otolaryngology, E-Da Hospital, Kaohsiung, Taiwan aff002;  Department of Medical Research, E-Da Hospital, Kaohsiung, Taiwan aff003;  Division of Hematology-Oncology, Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan aff004;  School of Medicine, I-Shou University, Kaohsiung, Taiwan aff005
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225537

Souhrn

There is high risk of metastasis and recurrence in head and neck squamous cell carcinoma (HNSCC) patients, especially for patient who received definitive surgery and adjuvant radiotherapy. Aberrant activation of PI3K/AKT/mTOR signaling occurs in approximately 80% of HNSCC, which has been indicated to serve as prognostic biomarkers for patients suffer from recurrence or metastasis. Therefore, in this study, we focus on the relationship between the expression level of signaling factors in PI3K/AKT/mTOR pathway and recurrence tumor from HNSCC patients. A tissue microarray (TMA) was constructed from 54 cases of HNSCC patients who received definitive surgery and adjuvant radiotherapy, are followed more than 5 years, and with no previous malignancy and synchronous tumor. Slides were scored and dichotomized by two pathologists and scores. Based on the TMA block with IHC staining, the results showed that PI3K/AKT/mTOR signaling was highly activated both in recurrence and non-recurrence patients. Particularly, in the recurrence population, the results showed the low expression phospho-eukaryotic initiation factor 4E (p-eIF4E) or high expression eIF4E, phospho-eIF4E binding protein 1 (p-4EBP1), phospho-ribosomal protein S6 kinase beta-1 (p-S6K1) and phospho-40S ribosomal protein S6 (p-S6R) exhibited worse overall survival. The expression level of eIF4E and p-4EBP1 were significantly associated with tumor recurrence and recurrence-free survival. Furthermore, high expression level of eIF4E and p-4EBP1 had worse recurrence-free survival. In conclusion, the expression of eIF4E and p-4EBP1 should be considered as predictive biomarkers for the HNSCC patients. This may contribute to potential predictive biomarkers for HNSCC patient who receive adjuvant radiotherapy.

Klíčová slova:

Biomarkers – Cell staining – Head and neck squamous cell carcinoma – Metastasis – Negative staining – Radiation therapy – Staining – Surgical and invasive medical procedures


Zdroje

1. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. Expert review of anticancer therapy. 2006;6(7):1111–8. doi: 10.1586/14737140.6.7.1111 16831082.

2. Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA oncology. 2017;3(4):524–48. doi: 10.1001/jamaoncol.2016.5688 27918777; PubMed Central PMCID: PMC6103527.

3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136(5):E359–86. doi: 10.1002/ijc.29210 25220842.

4. Hwang TZ, Hsiao JR, Tsai CR, Chang JS. Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995–2009. International journal of cancer. 2015;137(2):395–408. doi: 10.1002/ijc.29330 25395239.

5. Ram H, Sarkar J, Kumar H, Konwar R, Bhatt ML, Mohammad S. Oral cancer: risk factors and molecular pathogenesis. Journal of maxillofacial and oral surgery. 2011;10(2):132–7. doi: 10.1007/s12663-011-0195-z 22654364; PubMed Central PMCID: PMC3177522.

6. Worsham MJ. Identifying the risk factors for late-stage head and neck cancer. Expert review of anticancer therapy. 2011;11(9):1321–5. doi: 10.1586/era.11.135 21929305; PubMed Central PMCID: PMC3715314.

7. Georges P, Rajagopalan K, Leon C, Singh P, Ahmad N, Nader K, et al. Chemotherapy advances in locally advanced head and neck cancer. World journal of clinical oncology. 2014;5(5):966–72. doi: 10.5306/wjco.v5.i5.966 25493232; PubMed Central PMCID: PMC4259956.

8. Ribeiro IP, Caramelo F, Esteves L, Menoita J, Marques F, Barroso L, et al. Genomic predictive model for recurrence and metastasis development in head and neck squamous cell carcinoma patients. Scientific reports. 2017;7(1):13897. doi: 10.1038/s41598-017-14377-x 29066758; PubMed Central PMCID: PMC5654944.

9. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371(9625):1695–709. doi: 10.1016/S0140-6736(08)60728-X 18486742.

10. Kim YS. Reirradiation of head and neck cancer in the era of intensity-modulated radiotherapy: patient selection, practical aspects, and current evidence. Radiation oncology journal. 2017;35(1):1–15. doi: 10.3857/roj.2017.00122 28395502; PubMed Central PMCID: PMC5398346.

11. Kozakiewicz P, Grzybowska-Szatkowska L. Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. Oncology letters. 2018;15(5):7497–505. doi: 10.3892/ol.2018.8300 29725456; PubMed Central PMCID: PMC5920345.

12. Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, et al. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head & neck. 2016;38(12):1759–64. doi: 10.1002/hed.24501 27232378.

13. Takes RP, Rinaldo A, Silver CE, Piccirillo JF, Haigentz M Jr., Suarez C, et al. Future of the TNM classification and staging system in head and neck cancer. Head & neck. 2010;32(12):1693–711. doi: 10.1002/hed.21361 20191627.

14. Lee CC, Ho HC, Su YC, Yu CH, Yang CC. Modified Tumor Classification With Inclusion of Tumor Characteristics Improves Discrimination and Prediction Accuracy in Oral and Hypopharyngeal Cancer Patients Who Underwent Surgery. Medicine. 2015;94(27):e1114. doi: 10.1097/MD.0000000000001114 26166107; PubMed Central PMCID: PMC4504658.

15. Akhter M, Hossain S, Rahman QB, Molla MR. A study on histological grading of oral squamous cell carcinoma and its co-relationship with regional metastasis. Journal of oral and maxillofacial pathology: JOMFP. 2011;15(2):168–76. doi: 10.4103/0973-029X.84485 22529575; PubMed Central PMCID: PMC3329698.

16. Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert opinion on therapeutic targets. 2011;15(1):63–74. doi: 10.1517/14728222.2011.541440 21110697; PubMed Central PMCID: PMC3399735.

17. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110(2):163–75. doi: 10.1016/s0092-8674(02)00808-5 12150925.

18. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Current opinion in cell biology. 2005;17(6):596–603. doi: 10.1016/j.ceb.2005.09.009 16226444.

19. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes & development. 2002;16(12):1472–87. doi: 10.1101/gad.995802 12080086; PubMed Central PMCID: PMC186342.

20. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004;23(18):3189–99. doi: 10.1038/sj.onc.1207545 15094768.

21. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Molecular and cellular biology. 1993;13(12):7358–63. doi: 10.1128/mcb.13.12.7358 8246956; PubMed Central PMCID: PMC364806.

22. Jiang Y, Muschel RJ. Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer research. 2002;62(6):1910–4. 11912173.

23. Garcia-Carracedo D, Villaronga MA, Alvarez-Teijeiro S, Hermida-Prado F, Santamaria I, Allonca E, et al. Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. Oncotarget. 2016;7(20):29780–93. doi: 10.18632/oncotarget.8957 27119232; PubMed Central PMCID: PMC5045433.

24. Clark C, Shah S, Herman-Ferdinandez L, Ekshyyan O, Abreo F, Rong X, et al. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. The Laryngoscope. 2010;120(6):1159–65. doi: 10.1002/lary.20917 20513033; PubMed Central PMCID: PMC2997737.

25. Sethi K, Sarkar S, Das S, Rajput S, Mazumder A, Roy B, et al. Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. Journal of experimental therapeutics & oncology. 2011;9(3):187–99. 22070050.

26. Fisher SB, Patel SH, Kooby DA, Weber S, Bloomston M, Cho C, et al. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB: the official journal of the International Hepato Pancreato Biliary Association. 2012;14(8):514–22. doi: 10.1111/j.1477-2574.2012.00489.x 22762399; PubMed Central PMCID: PMC3406348.

27. Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, et al. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. Molecular cancer therapeutics. 2014;13(11):2738–50. doi: 10.1158/1535-7163.MCT-13-1090 25193510; PubMed Central PMCID: PMC4221385.

28. Hildebrandt MA, Lippman SM, Etzel CJ, Kim E, Lee JJ, Khuri FR, et al. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18(13):3705–13. doi: 10.1158/1078-0432.CCR-11-3271 22577058; PubMed Central PMCID: PMC3404728.

29. Millican-Slater RA, Sayers CD, Hanby AM, Hughes TA. Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer. British journal of cancer. 2016;115(3):339–45. doi: 10.1038/bjc.2016.178 27280636; PubMed Central PMCID: PMC4973151.

30. Blatt S, Voelxen N, Sagheb K, Pabst AM, Walenta S, Schroeder T, et al. Lactate as a predictive marker for tumor recurrence in patients with head and neck squamous cell carcinoma (HNSCC) post radiation: a prospective study over 15 years. Clinical oral investigations. 2016;20(8):2097–104. doi: 10.1007/s00784-015-1699-6 26728026.

31. Khan KH, Yap TA, Yan L, Cunningham D. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chinese journal of cancer. 2013;32(5):253–65. doi: 10.5732/cjc.013.10057 23642907; PubMed Central PMCID: PMC3845556.

32. Josse L, Xie J, Proud CG, Smales CM. mTORC1 signalling and eIF4E/4E-BP1 translation initiation factor stoichiometry influence recombinant protein productivity from GS-CHOK1 cells. The Biochemical journal. 2016;473(24):4651–64. doi: 10.1042/BCJ20160845 27760840; PubMed Central PMCID: PMC5147049.

33. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, et al. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Molecular cancer therapeutics. 2008;7(7):1782–8. doi: 10.1158/1535-7163.MCT-07-2357 18644990; PubMed Central PMCID: PMC2559956.

34. D'Abronzo LS, Ghosh PM. eIF4E Phosphorylation in Prostate Cancer. Neoplasia. 2018;20(6):563–73. doi: 10.1016/j.neo.2018.04.003 29730477; PubMed Central PMCID: PMC5994774.


Článek vyšel v časopise

PLOS One


2019 Číslo 11